The global imatinib drug market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). The major factor that is expected to accelerate the growth of the market includes an increase in the prevalence of cancer and an increase in demand for target drug therapy. For instance, according to National Cancer Institute in 2017, the number of new leukemia cases was 62,130 and the number of mortalities was 24,500 which is driving the adoption of the imatinib drug. In addition, the Imatinib drug is used for the treatment of patients with cancer by blocking the growth of eosinophils. This drug has been attributed owing to its higher efficacy in treating Chronic Eosinophilic Leukemia, Hyper-Eosinophilic Syndrome, Gastrointestinal Stromal Tumors (GIST), and many more. However, the high cost of imatinib as compared to several substitutes such as Tarceva, Sprycel, and Tasigna may hamper the market growth.

The incidences of chronic eosinophilic leukemia are expected to increase in the future. Chronic eosinophilic leukemia (CEL) is a disorder in which eosinophil count is greater than 1500 µl in peripheral blood also known as hyper-eosinophilia. It is a rare myeloproliferative neoplasm, overproduction of eosinophils in the bone marrow. Imatinib drug is more beneficial in patients who have leukemia from a genetic mutation. Moreover, the Imatinib drug also supports in improving blood counts and symptoms very fast which makes this drug highly adopted by the targeted patient pool. Imatinib for gastrointestinal stromal tumors (GIST) is also showing a significant share as Imatinib has been the first-line therapy for GIST. The drug targets KIT and PDGFRA (platelet-derived growth factor receptor A) proteins blocking the growth of tumor cells. 

Market Coverage

• The market number available for – 2020-2027
• Base year- 2020
• Forecast period- 2021-2027
• Segment Covered
• Regions Covered- Globally

Competitive Landscape: Sun Pharmaceutical Industries Ltd., Novartis International AG, and Teva Pharmaceutical Industries Ltd., among others. 

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominates the market in base year?
• Which segment and region will project fastest growth in the market?
• How COVID-19 impacted the market?

o Recovery Timeline

o Deviation from pre-COVID forecast

o Most affected region and segment

• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Imatinib Drug Market Report by Segment

By Drug Formulation

• Capsules

• Tablets

By Application

• Philadelphia Positive Chronic Myeloid Leukemia

• Myeloproliferative Diseases (MPD)

• Hyper-Eosinophilic Syndrome (HES)

• Myelodysplastic Syndrome (MDS)

• Gastrointestinal Stromal Tumors (GIST)

• Others

Global Imatinib Drug Market by Region